Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213791 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
A Phase 1 study of Breast Neoplasms and Cholangiocarcinoma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT07213791: Recruiting Phase 1 study of Breast Neoplasms and Cholangiocarcinoma, sponsored by Eli Lilly and Company.
NCT07213791 is a Phase 1 study of Breast Neoplasms and Cholangiocarcinoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 241 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213791, a Phase 1 study of Breast Neoplasms and Cholangiocarcinoma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Conditions Studied
Interventions
- DRUG LY4337713
Study Locations (20)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford University Medical Center - Stanford
Florida
- Biogenix Molecular, LLC - Miami
- Moffitt - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- BAMF Health Inc. - Grand Rapids
New York
- New York University (NYU) Clinical Cancer Center - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Texas
- Texas Oncology - DFW (Sammons CC) - Dallas
- Baylor College of Medicine - Houston
Indiana
- Indiana University (IU) School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2033-03 |
| Phase | Phase 1 |
What NCT07213791 shows while recruiting
NCT07213791 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (57% lower).
The record links to 7 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which LY4337713 is the first listed.
NCT07213791 names 20 study sites across 13 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07213791 about?
NCT07213791 is a clinical study titled "A Study of LY4337713 in Participants With FAP-Positive Solid Tumors". This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. ...
What is the current status of trial NCT07213791?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2025-10-22. Estimated completion is 2033-03.
What conditions does trial NCT07213791 study?
This clinical trial studies the following conditions: Breast Neoplasms, Cholangiocarcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Esophageal Neoplasms.
What interventions are being tested in trial NCT07213791?
The interventions under investigation include: LY4337713 (DRUG).
Who is sponsoring clinical trial NCT07213791?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213791 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07213791's enrollment target sits among peer trials
241 36th of 97 higher than 62 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI